deferiprone has been researched along with Muscular Dystrophy, Duchenne in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone treatment tended to decrease muscle iron levels in mdx mice (-30%, P < 0." | 1.72 | Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. ( Alves, FM; Ayton, S; Bush, AI; Caldow, MK; Chung, JD; Crouch, PJ; Hardee, JP; Hare, DJ; Koopman, R; Kysenius, K; Lynch, GS; Trieu, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, FM | 1 |
| Kysenius, K | 1 |
| Caldow, MK | 1 |
| Hardee, JP | 1 |
| Chung, JD | 1 |
| Trieu, J | 1 |
| Hare, DJ | 1 |
| Crouch, PJ | 1 |
| Ayton, S | 1 |
| Bush, AI | 1 |
| Lynch, GS | 1 |
| Koopman, R | 1 |
1 other study available for deferiprone and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy.
Topics: Animals; Deferiprone; Dystrophin; Ferritins; Fibrosis; Heme; Iron; Iron Chelating Agents; Iron Overl | 2022 |